Related Experiment Videos
Successful Treatment of Relapsed Pediatric Central Nervous System ALK+ Anaplastic Large Cell Lymphoma With Lorlatinib
Courtney M Vaughn1, Catherine Evers Smith2, Laura G Schuettpelz1
1Department of Pediatrics, Division of Pediatric Hematology Oncology.
Background:
Pediatric Anaplastic Lymphoma Kinase-driven (ALK+) Anaplastic Large Cell Lymphoma (ALCL) offers an exciting opportunity for targeted therapy. Standard frontline chemotherapy for ALK+ ALCL is associated with severe toxicities; ALK inhibition may provide an opportunity to decrease this toxicity and improve relapse outcomes.
Observation:
We present a patient with both a systemic and CNS relapse of her ALK+ ALCL who achieved complete remission with ALK inhibitor monotherapy.
Conclusion:
This case supports studying the inclusion of newer ALK inhibitors in upfront therapy for pediatric ALK+ ALCL and supports the use of Lorlatinib to treat CNS relapse of ALK+ ALCL.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...